The pharmaceutical company is in the middle of an early-stage clinical trial that is testing an antiviral therapy pill, administered orally, for the disease.
If successful and approved by the U.S. Food and Drug Administration, the drug could be distributed across the U.S. by the end of the year, Bourla said on the CNBC television show Squawk Box.
The pill could become the first home cure for a virus that has, in the past year, infected more than 149 million people worldwide and left at least three million dead.
Being able to take the pill at home, Bourla said, would be a ‘game-changer’.
Health experts, according to CNBC, are hopeful that the pill could treat people newly infected with the virus and save them the cost of hospital trips and treatment.
The drug contains an antiviral code called PF-07321332. Classified as a ‘protease inhibitor’, the code is designed to inhibit the ‘spine’ of the virus cell and prevent it from replicating in human cells.
Protease inhibitors have, in the past, been used to treat other viruses such as HIV and hepatitis C.
Researchers at Pfizer began work on the pill last summer and by July had developed the first seven milligrams — the size of a raindrop — of the compound, the company’s director of medicinal chemistry, Dafydd Owen, told a private symposium in March.
By late October, 100 grams of the compound had been created and two weeks later, more than a kilogram — all with the help wth 210 researchers.
The clinical trial has been scheduled to run for approximately five months, divided into three phases. Participants are healthy and clean-living and aged 18 to 60.
Phase 1 of the trial will test how well the drug is tolerated, if the dose quantities are increased, or taken alone or with ritonavir, according to documents obtained by the Daily Telegraph.
Phase 2 will test the same but with multiple doses, while Phase 3 will test tablet and liquid forms of the drug as well as the effect of eating after taking the drug.
Formal Phase 3 trials will also test whether the drug works against people who have been exposed to the virus.